Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2019-08-12 Earnings Release
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 100% confidence The document is a short announcement (2339 characters) that explicitly states the company has revised its financial guidance upwards and mentions that the detailed figures will be provided in the 'six-month interim report (Q2), which will be published tomorrow morning'. This structure—a brief update on results/outlook followed by a reference to the full report's publication date—is characteristic of an Earnings Release (ER), which provides key highlights before the comprehensive report (IR). It is not the full Interim Report (IR) itself, nor is it a general announcement about publishing a report (RPA), as it contains specific, material financial guidance changes. Therefore, Earnings Release (ER) is the most appropriate classification. H1 2019
2019-08-12 English
Regulatory Filings 2019
Regulatory Filings Classification · 90% confidence The document is a press release announcing a strategic partnership between ALK and Windgap Medical regarding a new epinephrine auto-injector for the US market. It details the strategy, market size, product features, and the agreement terms. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement concerning business strategy and potential future commercialization, which often falls under general corporate news. Since it is a specific business announcement that doesn't fit the defined categories like M&A (TAR), Capital (CAP), or Director's Dealing (DIRS), the most appropriate general category for significant corporate news that isn't a standard financial report or mandatory filing is Regulatory Filings (RNS) as a fallback for miscellaneous announcements, although it functions more like a strategic update. Given the options, and since it's a press release announcing a major business development rather than a specific financial report or mandatory filing type, RNS (Regulatory Filings/General Announcement) is the best fit among the provided codes for this type of corporate news release.
2019-08-09 English
Regulatory Filings 2019
Regulatory Filings Classification · 94% confidence The document is a press release written in Danish announcing a strategic partnership between ALK and Windgap Medical regarding a new epinephrine auto-injector for the US market. It details the agreement, market potential, and next steps (FDA submission). Crucially, at the end, it includes a section titled "Vedhæftet fil" (Attached file) with a link to a downloadable resource: "FM_13_19DK_09082019". Since the document itself is an announcement about a business development and strategy, and it explicitly points to an attached file (implying this text is the announcement wrapper), it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that this is a specific business development announcement rather than a standard financial report (like 10-K or IR), and it announces the publication of related material, RPA is a strong candidate if the attached file is the main report. However, since the content itself is a detailed strategic update and partnership announcement, and it is not explicitly stating that the *financial* results are attached, it is best classified as a general Regulatory Filing (RNS) which covers broad corporate news releases that don't fit other specific categories, or potentially an Investor Presentation (IP) if the attached file is a presentation. Given the nature of the announcement (strategic partnership, market entry, no specific financial period results mentioned), RNS is the most appropriate general category for non-standard corporate news releases, especially since it is not a standard financial report like 10-K or IR.
2019-08-09 Danish
ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from ALK-Abelló regarding a new strategic partnership with Windgap Medical for the development and commercialization of an epinephrine auto-injector in the US market. It details the business strategy, market potential, and contractual terms of the partnership. Since it is a general regulatory announcement regarding company strategy and business development that does not fit into specific categories like M&A (it is a partnership/licensing agreement) or Earnings Release, it is best classified as a general Regulatory Filing (RNS).
2019-08-09 Danish
ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA
Regulatory Filings Classification · 95% confidence The document is a company release (No 13/2019) announcing a strategic partnership and licensing agreement between ALK and Windgap Medical for the development and commercialization of a new epinephrine auto-injector. It details the business strategy, market potential, and contractual terms of the deal. Since it is a general corporate announcement regarding business strategy and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or financial reporting, it is classified as a Regulatory Filing (RNS) under the EU Market Abuse Regulation.
2019-08-09 English
ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
Regulatory Filings Classification · 95% confidence The document is a corporate announcement (Selskabsmeddelelse) from ALK-Abelló regarding the European regulatory approval of a new tablet vaccine (ITULAZAX). It is a standard regulatory disclosure under the EU Market Abuse Regulation. Since it does not fit into specific categories like financial results, dividends, or board changes, and is a formal regulatory announcement, it is classified as a Regulatory Filing (RNS).
2019-06-07 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.